Femtosecond laser versus mechanical keratome flaps in wavefront-guided laser in situ keratomileusis: prospective contralateral eye study.

PURPOSE To compare the outcomes of wavefront-guided laser in situ keratomileusis (LASIK) performed using the IntraLase femtosecond laser with the outcomes using the Hansatome mechanical microkeratome. SETTING Private clinic, Overland Park, Kansas, USA. METHODS In a prospective contralateral-eye study performed under institutional review board supervision, 51 consecutive patients (102 eyes) had bilateral wavefront-guided LASIK for myopia using the Alcon LADARVision laser. One eye of each patient was randomized to have the flap created with the IntraLase femtosecond laser and the other flap using a standard compression head Hansatome microkeratome. All other treatment parameters were the same. RESULTS The IntraLase group had significantly better mean uncorrected visual acuity (UCVA) at all intervals from 1 day to 3 months postoperatively. The mean spheroequivalent at 3 months was more myopic with the Hansatome (-0.34 diopter [D] +/- 0.28 [SD]) than with the IntraLase (-0.19 +/- 0.24 D) (P<.01). The mean residual astigmatism at 3 months was also significantly higher in the Hansatome group than in the IntraLase group (0.32 +/- 0.25 D and 0.17 +/- 0.20 D, respectively) (P<.01). The differences in UCVA persisted after spheroequivalent outcomes were controlled for but equilibrated when the analysis was modified to control for manifest postoperative astigmatism. Aberrometry showed significantly higher astigmatism and trefoil in the Hansatome group. Recovery of corneal sensation and epithelial integrity was similar between groups. CONCLUSIONS The statistically better UCVA and manifest refractive outcomes after LASIK with the IntraLase femtosecond laser may be the result of differences in postoperative astigmatism and trefoil. These findings are consistent with previous findings of better astigmatic outcomes with the IntraLase laser and may have clinical significance for wavefront-guided treatments.